📊 BEIGF Key Takeaways
Is BeOne Medicines Ltd. (BEIGF) a Good Investment?
BeOne Medicines demonstrates exceptional fundamental strength with 40.2% revenue growth, accelerating profitability (144.5% net income growth), and industry-leading gross margins of 87.5%. The company maintains fortress-like balance sheet metrics (3.41x current ratio, 0.19x debt/equity) while generating substantial free cash flow of $941.7M, providing significant financial flexibility for future growth initiatives.
BeOne Medicines shows high-quality fundamental improvement with 40.2% revenue growth, 144.5% net income growth, and nearly $942M of free cash flow, indicating scale is starting to convert into durable earnings and cash generation. The balance sheet is strong, with $4.55B in cash, low leverage, and ample liquidity, which supports continued R&D and commercial expansion. The main constraint is that profitability remains relatively modest for a pharmaceutical company, so sustaining margin expansion is critical.
Why Buy BeOne Medicines Ltd. Stock? BEIGF Key Strengths
- Exceptional revenue growth of 40.2% YoY indicates strong market demand and successful commercial execution
- Net income growth of 144.5% significantly outpaces revenue growth, demonstrating improving operational efficiency and operating leverage
- Superior gross margin of 87.5% typical of high-value pharmaceutical products with strong pricing power
- Robust free cash flow generation of $941.7M with 17.6% FCF margin provides financial flexibility
- Fortress balance sheet with 3.41x current ratio, low leverage (0.19x debt/equity), and $4.5B cash position
- Strong interest coverage of 9.0x indicates minimal refinancing risk
- Strong top-line and earnings growth with revenue up 40.2% and net income up 144.5% year over year
- Excellent financial health driven by $4.55B in cash, a 3.41x current ratio, and low debt-to-equity of 0.19x
- High gross margin of 87.5% and solid free cash flow generation of $941.74M support reinvestment capacity
BEIGF Stock Risks: BeOne Medicines Ltd. Investment Risks
- Operating margin of 8.4% significantly lags gross margin, suggesting high R&D or SG&A costs that may pressure profitability if revenue growth decelerates
- ROE of 6.6% and ROA of 3.5% are modest relative to revenue scale, indicating inefficient capital deployment or asset-heavy operations
- Pharmaceutical sector exposure to regulatory risks, patent expirations, and clinical trial uncertainties not captured in historical metrics
- High year-over-year growth rates may be unsustainable; deceleration could materially impact market perception and investment thesis
- Operating and net margins remain modest at 8.4% and 5.4%, leaving limited room for execution missteps
- Pharmaceutical fundamentals can be volatile due to R&D spending, regulatory outcomes, and product concentration risk
- ROE of 6.6% and ROA of 3.5% suggest capital efficiency is improving but not yet strong
Key Metrics to Watch
- Organic revenue growth rate and product-level performance to assess sustainability of 40.2% growth
- Operating margin expansion/contraction as a proxy for operational efficiency and R&D productivity
- Free cash flow conversion ratio to validate cash generation quality and reinvestment discipline
- R&D spending as percentage of revenue to monitor innovation pipeline health
- Inventory and accounts receivable trends to assess working capital management
- Operating margin and net margin trend
- Free cash flow and revenue growth sustainability
BeOne Medicines Ltd. (BEIGF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.41x current ratio provides a solid financial cushion.
BEIGF Profit Margin, ROE & Profitability Analysis
BEIGF vs Healthcare Sector: How BeOne Medicines Ltd. Compares
How BeOne Medicines Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is BeOne Medicines Ltd. Stock Overvalued? BEIGF Valuation Analysis 2026
Based on fundamental analysis, BeOne Medicines Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
BeOne Medicines Ltd. Balance Sheet: BEIGF Debt, Cash & Liquidity
BEIGF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: BeOne Medicines Ltd.'s revenue has grown significantly by 1,148% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.65 indicates the company is currently unprofitable.
BEIGF Revenue Growth, EPS Growth & YoY Performance
BEIGF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.0B | $1.3M | $0.08 |
| Q2 2025 | $929.2M | $1.3M | $0.06 |
| Q1 2025 | $751.7M | $1.3M | $0.00 |
| Q3 2024 | $781.3M | -$120.4M | $-0.09 |
| Q2 2024 | $595.3M | -$120.4M | $-0.09 |
| Q1 2024 | $447.8M | -$251.2M | $-0.19 |
| Q3 2023 | $387.6M | $215.4M | $0.15 |
| Q2 2023 | $341.6M | -$348.4M | $-0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BeOne Medicines Ltd. Dividends, Buybacks & Capital Allocation
BEIGF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for BeOne Medicines Ltd. (CIK: 0001651308)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BEIGF
What is the AI rating for BEIGF?
BeOne Medicines Ltd. (BEIGF) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BEIGF's key strengths?
Claude: Exceptional revenue growth of 40.2% YoY indicates strong market demand and successful commercial execution. Net income growth of 144.5% significantly outpaces revenue growth, demonstrating improving operational efficiency and operating leverage. ChatGPT: Strong top-line and earnings growth with revenue up 40.2% and net income up 144.5% year over year. Excellent financial health driven by $4.55B in cash, a 3.41x current ratio, and low debt-to-equity of 0.19x.
What are the risks of investing in BEIGF?
Claude: Operating margin of 8.4% significantly lags gross margin, suggesting high R&D or SG&A costs that may pressure profitability if revenue growth decelerates. ROE of 6.6% and ROA of 3.5% are modest relative to revenue scale, indicating inefficient capital deployment or asset-heavy operations. ChatGPT: Operating and net margins remain modest at 8.4% and 5.4%, leaving limited room for execution missteps. Pharmaceutical fundamentals can be volatile due to R&D spending, regulatory outcomes, and product concentration risk.
What is BEIGF's revenue and growth?
BeOne Medicines Ltd. reported revenue of $5.3B.
Does BEIGF pay dividends?
BeOne Medicines Ltd. does not currently pay dividends.
Where can I find BEIGF SEC filings?
Official SEC filings for BeOne Medicines Ltd. (CIK: 0001651308) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BEIGF's EPS?
BeOne Medicines Ltd. has a diluted EPS of $0.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BEIGF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, BeOne Medicines Ltd. has a BUY rating with 84% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BEIGF stock overvalued or undervalued?
Valuation metrics for BEIGF: ROE of 6.6% (sector avg: 15%), net margin of 5.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BEIGF stock in 2026?
Our dual AI analysis gives BeOne Medicines Ltd. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BEIGF's free cash flow?
BeOne Medicines Ltd.'s operating cash flow is $1.1B, with capital expenditures of $185.8M. FCF margin is 17.6%.
How does BEIGF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 5.4% (avg: 12%), ROE 6.6% (avg: 15%), current ratio 3.41 (avg: 2).